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Increased risk for metachronous gastric
adenocarcinoma following gastric MALT
lymphoma—A US population-based study
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Abstract
Background: Gastric mucosa-associated lymphoid tissue lymphoma (gMALT) and gastric adenocarcinoma (GC) are long-
term complications of chronic Helicobacter pylori (HP) gastritis. Treatment of HP infection induces remission in most patients
with gMALT. Endoscopic follow-up is not currently endorsed after complete remission. However, the risk of GC in these
patients is unclear.
Objective: The objective of this study is to estimate GC risk in gMALT patients.
Methods: The National Cancer Institute Surveillance, Epidemiology and End Results 13 (SEER) database-Nov 2014 Sub
(1992–2012) was used to identify adult patients diagnosed with gMALT between 1992 and 2012. The standardized incidence
ratio of second primary GC after a latency period of 12 months was calculated and compared to a reference SEER cohort of
identical age, sex and time period. The risk of GC in these patients was also stratified by latency period (five years) and age.
Results: We identified 2195 cases of gMALT lymphoma, and 20 (0.91%) of them subsequently developed GC with a relative
risk (RR) of 4.32 (95% CI 2.64–6.67) compared to the American population. The median latency time was five years and the
risk was maintained afterward (RR 4.92, 95% CI 2.45–8.79). When stratified by age group the risk was highest for the 45–64
group (RR 14.04, 95% CI 5.64–28.93).
Conclusion: gMALT lymphoma is associated with an increased risk of metachronous gastric adenocarcinoma. The risk is still
present after more than five years of follow-up. Further studies may clarify the most adequate follow-up strategy.
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Introduction
Adenocarcinomas represent the majority of gastric
malignancies, whereas lymphomas constitute 1%–7%
of all malignant tumors of the stomach.1,2 Gastric
adenocarcinoma (GC) is the fourth most common
cancer worldwide and the second cause of cancer-related
death.1,3 It is often diagnosed at an advanced stage and
has a low ﬁve-year survival rate.3 Gastric marginal zone
lymphomas of mucosa-associated lymphoid tissue, usu-
ally named gastric MALT lymphomas (gMALTs), are
indolent, low-grade B-cell non-Hodgkin’s lymphomas
classiﬁed as independent entities and considered to be
an infection-associated malignancy.4–6
Helicobacter pylori (HP) is the number one risk
factor for GC, probably due to chronic inﬂammation
of the mucosa, which leads to atrophic gastritis,
intestinal metaplasia and ultimately dysplasia and
adenocarcinoma.7,8 HP causes peptic ulcer, both intes-
tinal and diﬀuse type GC and gMALT.9,10
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The incidence of distal GC has been declining in high-
income countries, which can be due to the declining
prevalence of HP infection.11,12 Although gMALTs are
also strongly associated with HP infection, the incidence
of this disease has, in contrast to GC, been reported to
increase, probably due to improved endoscopic and histo-
logical diagnostic procedures.13 Incidence of gMALT is
relatively low in Western European countries, ranging
from 0.21 (England) to 13 (Italy) per 100,000.8,14,15
The relationship between the two types of cancer and
particularly whether patients with diagnosed gMALT
have an increased risk of developing GC is controversial.
Though that has been suggested by case series and small
cohorts,4,16–19 other studies were not able to support these
claims.13,20–22 A large study conducted in theNetherlands
using a nationwide database found that patients with
gMALT have a six-fold increased risk of GC when com-
pared to the general population (p< 0.001), and a 16.6
times higher risk for patients aged 45 to 59 compared to
the general population (p< 0.001).5
Current guidelines are contradictory regarding
follow-up endoscopy in patients with localized
gMALT in remission after HP eradication. Some guide-
lines recommend a follow-up based on clinical, and
physical examination and laboratory assessment for
ﬁve years. Endoscopy is not included in the assessment
after complete remission is attained.23
With this study, we aim to evaluate the risk of GC in
patients after a diagnosis of gMALT. Our hypothesis is
that the risk of GC is increased in gMALT patients
compared with an age- and sex-matched reference
population.
Materials and methods
National Cancer Institute Surveillance,
Epidemiology and End Results (SEER) database
We used the SEER Program (www.seer.cancer.gov)
SEER*Stat Database: Incidence – SEER 13 Regs
Research Data, Nov 2014 Sub (1992–2012) <Katrina/
Rita Population Adjustment> linked to County
Attributes – Total U.S., 1969–2013 Counties,
National Cancer Institute, DCCPS, Surveillance
Research Program, Surveillance Systems Branch,
released April 2015, based on November 2014 submis-
sion. The SEER database collects and maintains
high-quality cancer data from hospitals and cancer
treatment centers from the United States (US) with a
98% completeness rate. The SEER 13 database covers
approximately 13.4% of the US population (2010
census) with a total of 4,057,213 tumors from 13 geo-
graphic areas: San Francisco-Oakland, Connecticut,
Detroit (Metropolitan), Hawaii, Iowa, New Mexico,
Seattle (Puget Sound), Utah, Atlanta (Metropolitan),
San Jose-Monterey, Los Angeles, Alaska Natives and
Rural Georgia.
The event variable was ‘‘Site recode B ICD-O-3/
WHO 2008.’’
Statistical analysis
We used the multiple primary standardized incidence
ratio (MP-SIR) session of Surveillance Research
Program, National Cancer Institute SEER*Stat software
(seer.cancer.gov/seerstat) version 8.2.1 April 7, 2015, to
calculate the standardized incidence ratio (SIR) and abso-
lute excess risk (AER). The database used was the SEER.
The expected gastric cancer (GC) incidence was calcu-
lated for a reference SEER cohort of identical age, sex
and time period. We also stratiﬁed the analysis by latency
period (ﬁve years after the latency exclusion period equal-
ing six years after gMALT recode in the database), by
gender and by age (0–44, 45–64, 65–84 and> 84).
Continuous data are presented either as mean or
median (interquartile range (IQR)) and dichotomous
or categorical data as proportions. SIR or relative
risk (RR) is presented as risk with 95% conﬁdence
intervals (CIs). A p value< 0.05 was considered statis-
tically signiﬁcant.
Patient selection
All patients with a histologically conﬁrmed diagnosis of
gMALT between 1992 and 2012 were included. We
excluded patients who were diagnosed with gMALT
diagnosis at autopsy or lost to follow-up. Patients
with GC diagnosis within 12 months of gMALT
lymphoma diagnosis were excluded as the GC was con-
sidered to be the prevalent disease.
The selection criteria, using ﬁrst record matching
selection criteria, were {Site and
Morphology.Lymphoma subtype recode/WHO 2008}
¼ (a)2.5.2 Extranodal MZL, MALT type’ AND {Site
and Morphology.Primary Site - labeled}¼ ’C16.0-
Cardia, NOS’,’C16.1-Fundus of stomach’,’C16.2-Body
of stomach’,’C16.3-Gastric antrum’,’C16.4-Pylorus’,’
C16.5-Lesser curvature of stomach NOS’,’C16.6-
Greater curvature of stomach NOS’,’C16.8-
Overlapping lesion of stomach’,’C16.9-Stomach, NOS’.
Patients were followed from diagnosis of gMALT to
the last known vital status, death or the last point of data
collection. Within this cohort, all patients with a histo-
logically conﬁrmed diagnosis of GC were identiﬁed.
Primary endpoint
The primary endpoint was the development of meta-
chronous GC at least 12 months after gMALT
diagnosis.
474 United European Gastroenterology Journal 5(4)
Results
Between 1992 and 2012, 2597 patients with a gMALT
diagnosis were identiﬁed from a population of
823,381,278 person-years. The ﬁnal cohort included
2195 cases of newly diagnosed gMALT, after exclusion
of 12 cases of diagnosis after ﬁrst record matching, 132
cases with an index record start date before the study
initiation and 258 cases in which the date of last contact
fell within the latency exclusion criteria of 12 months
(Figure 1). The overall incidence of gMALT in the
SEER population was 2.81/1,000,000, the lowest inci-
dence was 0 in 1992 and the highest was 4.43/1,000,000
in 2002. Median follow-up time of the entire cohort
was ﬁve (IQR 3–10) years reaching 13,186.07 person-
years at risk.
Baseline characteristics are shown in Table 1.
In total, 20 (0.91%) gMALT patients (12 males,
eight females) were diagnosed with metachronous gas-
tric adenocarcinoma (GC) at a mean age of 69.71 years.
The RR for GC after gMALT was 4.05 (95% CI 2.09–
7.08) in males and 4.79 (95% CI 2.07–9.44) in females.
When stratiﬁed by age group the risk was highest for
the 45–64 group (RR 14.04, 95% CI 5.64–28.93)
(Table 2).
The average number of GC diagnosis was two cases
per year, and the age standardized incidence rate was
0.002 per 100,000 per year. The proportions according
to ethnicity were 75% white, 15% black and 10%
other. The median interval between GC and gMALT
in patients with GC development after diagnosis of
gMALT was 63.5 (IQR 25-89) months (Table 1).
Overall, patients with a diagnosis of gMALT were at
a 4.32 times (95% CI 2.64–6.67) higher risk of develop-
ing GC compared to the general population of identical
age, sex and time period. The RR was increased even
after ﬁve years from gMALT diagnosis with an RR for
GC of 4.92 (95% CI 2.45–8.79, p< 0.05) (Table 3).
Discussion
This study provides long-term data on a relevant
national database representative of a Western popula-
tion and conﬁrms the suggestion from previous reports
that gMALT patients have a considerably higher GC
risk than the general population. We have shown that
this risk seems to peak at ﬁve years after gMALT diag-
nosis. Our study also allowed us to see a diﬀerence
across age groups with the highest risk for metachro-
nous GC in those aged 45 to 64 years.
Several small studies observed either the occurrence
of synchronous or metachronous GC in gMALT
patients or progression from premalignant states to
gastric carcinoma in such patients.2,5,10,18,24 In these




12 cases: diagnosis after first record matching
132 cases: index record start date before study initiation
258 cases: date of last contact within the latency period of 12 months
All adult patients with histologically confirmed diagnosis of gMALT in 
the 1992-2012 registry were included.
Patients who were diagnosed with gMALT at autopsy or lost to 
follow-up were excluded.
2195 subjects with newly
diagnosed gMALT
Figure 1. Flowchart of the population selection gMALT: gastric mucosa-associated lymphoid tissue lymphoma.
Table 1. Baseline characteristics of patients with a newly
diagnosed gastric MALT (gMALT) lymphoma (n¼ 2195) and the
subgroup of patients with a metachronous gastric cancer (GC)








Male gender, n (%) 1058 (48.2) 12 (60)
Female gender, n (%) 1137 (51.8) 8 (40)
White race, n (%) 1704 (77.6) 15 (75)
Black race, n (%) 209 (9.5) 3 (15)
Other, n (%) 282 (12.8) 2 (10)
Median age at time
of diagnosis, years (IQR)
67 (61, 78) 69 (58, 78)
Median latency time,
months (IQR)
– 63.5 (25, 89)
MALT: mucosa-associated lymphoid tissue lymphoma; IQR: interquartile
range.
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adenocarcinoma, and additionally most of the GC
reported were early cancers, suggesting lymphoma
developed before carcinoma.25
A long-term nationwide study of a Dutch popula-
tion suggested that gMALT patients had an important
increased risk for developing GC when compared to the
general population (six times higher risk), especially
for female and younger patients (45–59 years).5
Furthermore, the authors also reported that GC risk
was independent of the gMALT grade.5 Similarly, a
German prospective multicenter trial showed an 8.6
times higher morbidity ratio from GC compared with
the general German population and a 18.6 times higher
morbidity ratio from non-Hodgkin’s lymphoma.4
Our results showed a 4.3 times higher risk of
developing GC compared to the general American
population of identical age, sex and time period. The
median latency time for development of GC after
gMALT diagnosis was 63.5 months. These results
show a longer latency period compared to a previous
case review on metachronous occurrence of adenocar-
cinoma in gMALT patients, which reported latencies
from six months to ﬁve years.17 Our study, as in the
Dutch national study, also supports the hypothesis that
the risk is higher at younger ages (45–64) but failed to
demonstrate the association with gender.
An important question is the pathogenicity of the
two diﬀerent malignancies. HP infection is thought to
be a common etiological agent for both cancers.25 On
the one hand, HP infection induces chronic gastritis
with activation of neutrophils that produce nitric
oxide and superoxides, resulting in DNA damage and
eventually gastric carcinogenesis.26 On the other
hand, HP induces T-cell activation, lymphoid follicle
formation and B-cell hyperproliferation, eventually
leading to gMALT lymphoma development.27 The
common ﬁnding in the background of the carcinomat-
ous and lymphomatous lesions is severe inﬁltration of
lymphocytes.
There have been some reports of GC arising in the
same anatomic localization of gMALT, most of them
showing residual lymphoma cells in the gastrectomy
specimen.16,28 Ioachim et al.29 suggested that an
immunological imbalance caused by the lymphoma
could contribute to the development of dysplastic epi-
thelial cells. Furthermore, even if the GC arises in a
diﬀerent anatomical location, a previous gMALT may
constitute a marker of chronic inﬂammation, a prema-
lignant lesion similar to atrophy and/or intestinal
metaplasia.
Currently, it is established that HP eradication is not
suﬃcient to prevent GC in all cases. HP infection must
be cured early in order to prevent development of atro-
phy and/or intestinal metaplasia, precancerous condi-
tions that might not be reversible after HP
eradication.25,30 In the setting of gMALT lymphoma,
HP eradication is widely recognized as the initial treat-
ment.21 A further problem is that even after successful
HP eradication and gMALT remission, the risk of
developing GC might still be increased.16,25 Wu¨ndisch
Table 2. The relative risk of gastric cancer (GC) in patients with gastric MALT lymphoma (gMALT) as compared to the general population,





incidence Relative risk (RR) (95% CI)
Person-years
at risk
0–44 0 0 n/a 843.25
45–64 7 0.50 14.04a, (5.64–28.93) 4060.55
65–84 10 2.97 3.36a, (1.61–6.18) 6553.41
>84 3 1.14 2.63, (0.54–7.69) 1728.85
Overall 20 4.63 4.32a, (2.64–6.67) 13,186.07
ap< 0.05. MALT: mucosa-associated lymphoid tissue lymphoma; CI: confidence interval.
Table 3. The relative risk of gastric cancer (GC) in patients with gastric MALT lymphoma (gMALT) as compared to the general population,






risk (RR) 95% CI
Person-years
at risk
Overall 20 4.63 4.32a 2.64–6.67 13,186.07
<5 years of latency 9 2.39 3.76a 1.72–7.14 6915.77
5 years of latency 11 2.24 4.92a 2.45–8.79 6270.30
ap< 0.05. MALT: mucosa-associated lymphoid tissue lymphoma; CI: confidence interval.
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et al.4 reported on three of 120 patients (3%) with HP-
associated gMALT lymphoma who developed early
GC four to ﬁve years after complete lymphoma remis-
sion following HP eradication. In this study endoscopic
controls were carried out at monthly intervals, and
after gMALT remission, endoscopy was performed
every six to 12 months. All three cases were managed
successfully using mucosectomy, strongly supporting
the need for long-term endoscopic follow-up in
responding patients with gMALT.4
Current guidelines are contradictory regarding
follow-up endoscopies in patients with localized
gMALT in remission. The National Comprehensive
Cancer Network (NCCN)23 advises endoscopy revision
three months after HP eradication, and in cases of HP-
negative gMALT remission, maintaining only clinical
follow-up, reserving endoscopy for symptomatic
patients. On the contrary, European Society for
Medical Oncology (ESMO) guidelines31 advise follow-
up endoscopies every six months for two years. The
American Society for Gastrointestinal Endoscopy
(ASGE) guidelines recommend extended surveillance
both with endoscopy and tissue sampling after
successful HP eradication.32 The rationale for this
recommendation is that complete regression of
gMALT may require a long period of time and
there is also a risk of recurrence, even without HP
reinfection.32 In a large international series by
Fischbach et al.,13 a watch-and-wait follow-up strat-
egy using endoscopy and mucosal sampling every
three to six months for the ﬁrst two years after HP
eradication with extension to every six to 12 months
thereafter identiﬁed a low rate of gMALT progres-
sion, based on a median follow-up of 42.2 months.
Therefore, the long-term follow-up is uncertain. In
this study, we realized that patients with a prior
gMALT more than ﬁve years before were still at
increased risk for GC. This may be taken into
account for the follow-up of these patients, lowering
the threshold for endoscopic examinations.
One of the main limitations of this study is the lack
of comparison of our cohort with HP-positive
patients.5,33 Previous studies showed that HP-positive
individuals have an estimated lifetime risk for GC of
1%,34 and that premalignant conditions associated with
HP infections are associated with a risk of 2% to 3% of
developing GC in a 10-year period,33 but direct com-
parisons are lacking. Capelle et al.5 showed that the risk
for GC in gMALT patients was very similar to patients
with atrophic gastritis and intestinal metaplasia.
Additionally, it would be important to know whether
such precancerous lesions were present in the histo-
logical samples surrounding gMALT lymphoma. To
overcome this limitation we used a 12-month latency
period.
Similarly, it would have been important to access the
type of treatment gMALT patients underwent since
there is a previous study that showed that patients trea-
ted with radiotherapy and/or chemotherapy had an
increased risk of GC.35 However, in the last 15 years
the majority of gMALT patients have been treated
almost exclusively by HP eradication with antibiotics.
In conclusion, although HP infection is decreasing in
prevalence with high response to eradication treatment,
this bacterium is associated with higher risk for
gMALT and GC. Currently there is debate regarding
the optimal endoscopic follow-up in this setting.
We have shown that the risk is higher for those aged
45–64 and that it peaks at ﬁve years after gMALT
diagnosis but is still increased afterward. Our ﬁndings
reinforce the necessity of not only short- but also long-
term follow-up after the diagnosis of gMALT, with
meticulous endoscopic and histological re-evaluations.
In the future, guidelines should take into account not
only the risk of gMALT lymphoma relapse/non-
response but also the risk of GC. A large prospective
study of patients with gMALT is essential to evaluate
patients at high risk of developing GC, and deﬁne the
optimal follow-up timing.
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